Leigha Senter

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2045904/publications.pdf

Version: 2024-02-01

66 papers	5,358 citations	147801 31 h-index	106344 65 g-index
69 all docs	69 docs citations	69 times ranked	8521 citing authors

#	Article	IF	Citations
1	Improving the quality of care for patients with advanced epithelial ovarian cancer: Program components, implementation barriers, and recommendations. Cancer, 2022, 128, 654-664.	4.1	10
2	Hospital-based ovarian cancer patient traceback program results in minimal genetic testing uptake. Gynecologic Oncology, 2022, 164, 615-621.	1.4	2
3	Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants. Journal of Clinical Oncology, 2022, 40, 1529-1541.	1.6	90
4	Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation. Gynecologic Oncology, 2022, 164, 514-521.	1.4	8
5	Risk assessment and genetic counseling for Lynch syndrome â€“ Practice resource of the National Society of Genetic Counselors and the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer. Journal of Genetic Counseling, 2022, 31, 568-583.	1.6	7
6	The risks of breast and ovarian cancer associated with the Ashkenazi Jewish founder allele <scp>BRCA2 6174delT</scp>. Clinical Genetics, 2022, 101, 317-323.	2.0	0
7	Bilateral Oophorectomy and the Risk of Breast Cancer in BRCA1 Mutation Carriers: A Reappraisal. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 1351-1358.	2.5	3
8	The impact of a cascade testing video on recipientsâ€™ knowledge, cognitive message processing, and affective reactions: A formative evaluation. Journal of Genetic Counseling, 2021, 30, 656-664.	1.6	6
9	Breast cancer risk after age 60 amongÂBRCA1 andÂBRCA2 mutation carriers. Breast Cancer Research and Treatment, 2021, 187, 515-523.	2.5	5
10	Survival from breast cancer in women with a BRCA2 mutation by treatment. British Journal of Cancer, 2021, 124, 1524-1532.	6.4	12
11	Abstract 878: Contraceptive use and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers: A prospective cohort study. Cancer Research, 2021, 81, 878-878.	0.9	1
12	Weight Gain and the Risk of Ovarian Cancer in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 2038-2043.	2.5	6
13	Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. Cancer Research, 2020, 80, 624-638.	0.9	39
14	Predictors of risk-reducing surgery intentions following genetic counseling for hereditary breast and ovarian cancer. Translational Behavioral Medicine, 2020, 10, 337-346.	2.4	9
15	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nature Genetics, 2020, 52, 56-73.	21.4	120
16	Does preventive oophorectomy increase the risk of depression in BRCA mutation carriers?. Menopause, 2020, 27, 156-161.	2.0	5
17	Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation. Gynecologic Oncology, 2020, 159, 820-826.	1.4	10
18	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. Genetics in Medicine, 2020, 22, 1653-1666.	2.4	82

#	Article	IF	Citations
19	GWAS of thyroid stimulating hormone highlights pleiotropic effects and inverse association with thyroid cancer. Nature Communications, 2020, 11, 3981.	12.8	86
20	Advancing the genetic counseling profession through research: Identification of priorities by the National Society of Genetic Counselors research task force. Journal of Genetic Counseling, 2020, 29, 884-887.	1.6	9
21	Niraparib maintenance in frontline management of ovarian cancer: a cost effectiveness analysis. International Journal of Gynecological Cancer, 2020, 30, 1569-1575.	2.5	10
22	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nature Genetics, 2020, 52, 572-581.	21.4	265
23	Characterization of the Cancer Spectrum in Men With GermlineBRCA1andBRCA2Pathogenic Variants. JAMA Oncology, 2020, 6, 1218.	7.1	48
24	Factors associated with use of hormone therapy after preventive oophorectomy in BRCA mutation carriers. Menopause, 2020, 27, 1396-1402.	2.0	8
25	The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. Npj Breast Cancer, 2019, 5, 38.	5.2	28
26	An alternative approach to establishing unbiased colorectal cancer risk estimation in Lynch syndrome. Genetics in Medicine, 2019, 21, 2706-2712.	2.4	11
27	Understanding BRCA Mutation Carriersâ€™ Preferences for Communication of Genetic Modifiers of Breast Cancer Risk. Journal of Health Communication, 2019, 24, 377-384.	2.4	7
28	Exploring genetic counselorsâ€™ perceptions of usefulness and intentions to use refined risk models in clinical care based on the Technology Acceptance Model (TAM). Journal of Genetic Counseling, 2019, 28, 664-672.	1.6	4
29	International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation. British Journal of Cancer, 2019, 121, 15-21.	6.4	101
30	Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2019, 175, 443-449.	2.5	12
31	Fine mapping of 14q13 reveals novel variants associated with different histological subtypes of papillary thyroid carcinoma. International Journal of Cancer, 2019, 144, 503-512.	5.1	4
32	Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers. JAMA Oncology, 2018, 4, 1059.	7.1	121
33	Mutational spectrum in a worldwide study of 29,700 families withBRCA1orBRCA2mutations. Human Mutation, 2018, 39, 593-620.	2.5	224
34	â€œSecondâ€Class Status?â€•Insight into Communication Patterns and Common Concerns Among Men with Hereditary Breast and Ovarian Cancer Syndrome. Journal of Genetic Counseling, 2018, 27, 885-893.	1.6	16
35	Involvement and Influence of Healthcare Providers, Family Members, and Other Mutation Carriers in the Cancer Risk Management Decisionâ€Making Process of BRCA1 and BRCA2 Mutation Carriers. Journal of Genetic Counseling, 2018, 27, 1291-1301.	1.6	6
36	Prospective evaluation of body size and breast cancer risk among BRCA1 and BRCA2 mutation carriers. International Journal of Epidemiology, 2018, 47, 987-997.	1.9	11

#	Article	IF	Citations
37	National Society of Genetic Counselors Code of Ethics: Explication of 2017 Revisions. Journal of Genetic Counseling, 2018, 27, 9-15.	1.6	7
38	Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation. Gynecologic Oncology, 2018, 150, 85-91.	1.4	65
39	Age at first full-term birth and breast cancer risk in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2018, 171, 421-426.	2.5	10
40	Neck Ultrasound in Patients with Follicular Thyroid Carcinoma. Hormones and Cancer, 2018, 9, 433-439.	4.9	10
41	A genome-wide association study yields five novel thyroid cancer risk loci. Nature Communications, 2017, 8, 14517.	12.8	117
42	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	21.4	356
43	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	21.4	289
44	Genetic consultation embedded in a gynecologic oncology clinic improves compliance with guideline-based care. Gynecologic Oncology, 2017, 147, 110-114.	1.4	46
45	Thyroglobulin Liquid Chromatographyâ€“Tandem Mass Spectrometry Has a Low Sensitivity for Detecting Structural Disease in Patients with Antithyroglobulin Antibodies. Thyroid, 2017, 27, 74-80.	4.5	44
46	Bilateral Oophorectomy and Breast Cancer Risk inBRCA1andBRCA2Mutation Carriers. Journal of the National Cancer Institute, 2017, 109, .	6.3	160
47	Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. Journal of Clinical Oncology, 2017, 35, 2240-2250.	1.6	152
48	Variants in microRNA genes in familial papillary thyroid carcinoma. Oncotarget, 2017, 8, 6475-6482.	1.8	8
49	HABP2 G534E Variant in Papillary Thyroid Carcinoma. PLoS ONE, 2016, 11, e0146315.	2.5	31
50	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Research, 2016, 18, 15.	5.0	88
51	Nurse practitioners & genetic counselors. Nurse Practitioner, 2016, 41, 43-49.	0.3	6
52	Genome-Wide Expression Screening Discloses Long Noncoding RNAs Involved in Thyroid Carcinogenesis. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4005-4013.	3.6	47
53	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nature Communications, 2016, 7, 11375.	12.8	93
54	Papillary Thyroid Carcinoma: Association Between Germline DNA Variant Markers and Clinical Parameters. Thyroid, 2016, 26, 1276-1284.	4.5	32

#	Article	IF	Citations
55	Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a caseâ€“control study. Breast Cancer Research and Treatment, 2016, 155, 365-373.	2.5	55
56	SomaticMED12mutations are associated with poor prognosis markers in chronic lymphocytic leukemia. Oncotarget, 2015, 6, 1884-1888.	1.8	49
57	Association of Type and Location ofBRCA1andBRCA2Mutations With Risk of Breast and Ovarian Cancer. JAMA - Journal of the American Medical Association, 2015, 313, 1347.	7.4	390
58	Weight Gain After Oophorectomy Among Women with a BRCA1 or BRCA2 Mutation. Women's Health, 2015, 11, 453-459.	1.5	2
59	Factors influencing ovulation and the risk of ovarian cancer in <scp>BRCA1</scp> and <scp>BRCA2</scp> mutation carriers. International Journal of Cancer, 2015, 137, 1136-1146.	5.1	56
60	Impact of Oophorectomy on Cancer Incidence and Mortality in Women With a BRCA1 or BRCA2 Mutation. Journal of Clinical Oncology, 2014, 32, 1547-1553.	1.6	523
61	Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. PLoS Genetics, 2013, 9, e1003212.	3.5	244
62	Genetic Testing by Cancer Site. Cancer Journal (Sudbury, Mass), 2012, 18, 334-337.	2.0	13
63	Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 134-147.	2.5	513
64	Consumer awareness and attitudes about insurance discrimination post enactment of the Genetic Information Nondiscrimination Act. Familial Cancer, 2012, 11, 637-644.	1.9	66
65	Epitope-positive truncating MLH1 mutation and loss of PMS2: implications for IHC-directed genetic testing for lynch syndrome. Familial Cancer, 2009, 8, 501-504.	1.9	16
66	The Clinical Phenotype of Lynch Syndrome Due to Germ-Line PMS2 Mutations. Gastroenterology, 2008, 135, 419-428.e1.	1.3	480